Company Presents Data on Menstrual Stem Cells at International Forums on Anti-Aging, Transfusion Medicine & Cellular Therapy OLDSMAR, Fla., Sept. 10 /PRNewswire-FirstCall/ -- Cryo-Cell International will present cutting edge research on menstrual stem cells (known as MenSCs) during two global scientific conferences this fall: The European Conference on Anti-Aging and Aesthetic Medicine (ECAAAM), September 11-14 in Dusseldorf, Germany, and the Annual Meeting of the AABB (Advancing Transfusion Medicine and Cellular Therapy Worldwide), October 4-7 in Montreal, Canada. "These meetings are important opportunities for us to engage in scientific dialogue about the promise of our menstrual blood stem cells, specifically demonstrating their potential future applicability in a wide area of therapeutics and medicine," said Julie Allickson, Ph.D., Vice President of Laboratory Operations and Research and Development at Cryo-Cell. During the ECAAAM conference, Cryo-Cell will address how early research is suggesting a role for these important stem cells in anti-aging medicine. The meeting will cover advances in anti-aging and aesthetic medicine technologies, and will highlight innovative new developments in stem cell therapies. The AABB meeting in October will showcase advances in blood banking, transfusion medicine and cellular and related biologic therapies. Cryo-Cell's extensive experience in cord blood banking and novel MenSC research and development will contribute to the discussions in advancing transfusion practices and improving patient outcomes. Cryo-Cell will also be presenting data related to the proliferative capacity of MenSCs. Cryo-Cell International continues to build a robust intellectual property (IP) portfolio on MenSCs while expanding its fast-emerging network of global research partnerships. Early studies of the stem cells in menstrual blood have confirmed that they have the capability to differentiate rapidly and plentifully into important cells, such as bone, cartilage, fat, nerve and cardiogenic cells. These are non-controversial adult stem cells that are easy to extract and cause no pain to the donor, making them an important and potentially valuable alternative to other stem cell sources. With additional studies, the use of these cells may lead to treatments for a number of serious diseases, such as stroke, Alzheimer's and Parkinson's disease. The cells may even one day be used for customized anti-aging or sports medicine treatments. Cryo-Cell's C'elle(SM) service, which was first introduced in November, 2007, is the first available product that enables women to collect menstrual flow containing stem cells, which can then be cryogenically preserved in a manner similar to stem cells from umbilical cord blood. About Cryo-Cell International, Inc. (OTCBB: CCEL.OB) Based in Oldsmar, Florida, with over 155,000 clients worldwide, Cryo-Cell is one of the largest and most established family cord blood banks. ISO 9001:2000 certified and accredited by the AABB, Cryo-Cell operates in a state- of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)- compliant facility. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. For more information, please call 1-800-STOR-CELL (1-800-786- 7235) or visit http://www.cryo-cell.com/. Forward-Looking Statement Statements wherein the terms "believes", "intends", "projects" or "expects" as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the uncertainty of market acceptance of any potential service offerings relating to types of stem cells other than cord blood stem cells, including the C'elle service, given that menstrual stem cells and other new stem cells have not yet been used in human therapies, and treatment applications using such stem cells are not likely to be developed and commercialized for many years and are subject to further research and development; the need for additional development and testing before determining the ultimate commercial value of the Company's intellectual property relating to the menstrual stem cells; the need to complete certain developments, including completion of clinical validation and testing, before any new process other than C'elle can be commercialized, and the Company's development of its final business and economic model in offering any such service; any adverse effect or limitations caused by recent increases in government regulation of stem cell storage facilities; any increased competition in our business; any decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease in the number of people paying annual storage fees; any adverse impacts on our revenue or operating margins due to the costs associated with increased growth in our business, including the possibility of unanticipated costs relating to the operation of our new facility; any technological breakthrough or medical breakthrough that would render the Company's business of stem cell preservation obsolete; any material failure or malfunction in our storage facilities; any natural disaster such as a tornado, other disaster (fire) or act of terrorism that adversely affects stored specimens; the costs associated with defending or prosecuting litigation matters and any material adverse result from such matters; decreases in asset valuations; any continued negative effect from adverse publicity in the past year regarding the Company's business operations; any negative consequences resulting from deriving, shipping and storing specimens at a second location; and other risks and uncertainties. The foregoing list is not exhaustive, and the Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-KSB, Quarterly Reports on Form 10-QSB and any Current Reports on Form 8-K filed by the Company. Contact: General Media Inquiries Kristin O'Neill 312-233-1295 Financial Media Inquiries Mona Walsh 212-704-4598 DATASOURCE: Cryo-Cell International, Inc. CONTACT: General Media Inquiries: Kristin O'Neill, +1-312-233-1295, , or Financial Media Inquiries: Mona Walsh, +1-212-704-4598, , both for Cryo-Cell International, Inc. Web site: http://www.cryo-cell.com/

Copyright